ALX Oncology Holdings Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $266.9M
- Price
- $2.04
- % Change (Daily % change from the live per-ticker quote feed.)
- +4.02%
- Volume
- 410.9K
About
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Quick stats
Shares outstanding138.3M
Computed float88.9M
Float / shares64.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001810182
Websitehttps://www.alxoncology.com
AI Summary
AI-generated1/11
standardbullishearnings
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
ALX Oncology reported a Q2 net loss of $18.0 million ($0.13 per share), narrowing from the prior year, driven by lower R&D expenses. The company holds $153.4 million in cash, sufficient to fund operations into the first half of 2028.
Operationally, the ASPEN-09-Breast Phase 2 trial remains on track for a mid-2027 data readout, and the Phase 1 trial for ALX2004 is enrolling patients with safety data expected in the second half of 2026.
The company appointed Scott Garland as Chairman and Michael Listgarten as General Counsel, while refinancing debt to establish a $50 million facility with HSBC to lower capital costs.